Last 7 days
-7.3%
Last 30 days
-3.8%
Last 90 days
-35.1%
Trailing 12 Months
-45.1%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
HCA | 70.6B | 60.2B | -4.86% | -6.89% | 12.5 | 1.17 | 2.52% | -18.88% |
LH | 19.6B | 14.9B | -11.65% | -18.57% | 15.35 | 1.32 | -7.72% | -46.20% |
DGX | 15.5B | 9.9B | -9.17% | -4.78% | 16.43 | 1.57 | -8.39% | -52.58% |
MID-CAP | ||||||||
UHS | 8.8B | 13.4B | -20.72% | -21.03% | 13 | 0.66 | 5.99% | -31.87% |
EHC | 5.3B | 4.3B | -15.50% | -2.92% | 19.39 | 1.21 | 8.31% | -34.26% |
LHCG | 5.2B | 2.3B | 3.17% | 35.63% | 86.23 | 2.28 | 2.85% | -58.05% |
ENSG | 5.0B | 3.0B | -3.25% | 4.25% | 22.21 | 1.65 | 15.15% | 15.43% |
AMN | 3.6B | 5.2B | -10.88% | -15.90% | 8.03 | 0.68 | 31.60% | 35.63% |
GH | 2.9B | 449.5M | -3.81% | -45.08% | -4.43 | 6.45 | 20.31% | -70.12% |
AMED | 2.5B | 2.2B | -17.56% | -48.92% | 20.74 | 1.11 | 0.41% | -43.27% |
SMALL-CAP | ||||||||
RDNT | 1.3B | 1.4B | 12.22% | 10.36% | 120.12 | 0.89 | 8.74% | -56.93% |
BKD | 524.3M | 2.8B | -3.12% | -59.80% | -2.2 | 0.19 | 2.43% | -140.13% |
ENZ | 58.0M | 98.8M | -21.26% | -67.11% | -2.18 | 0.59 | -14.50% | -605.55% |
XGN | 38.5M | 45.4M | -7.42% | -70.30% | -0.96 | 0.85 | -5.93% | -72.41% |
PMD | 33.4M | 26.0M | 7.45% | -10.59% | -16.54 | 1.28 | 9.09% | -588.38% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 4.4% | 449,538,000 | 430,755,000 | 408,130,000 | 391,087,000 | 373,653,000 |
S&GA Expenses | 7.9% | 299,828,000 | 278,004,000 | 247,862,000 | 221,975,000 | 191,881,000 |
R&D Expenses | 9.9% | 373,807,000 | 340,250,000 | 311,201,000 | 289,470,000 | 263,221,000 |
EBITDA | -11.4% | -614,910,000 | -551,958,000 | -501,772,000 | -374,508,000 | - |
EBITDA Margin | -6.8% | -1.37 | -1.28 | -1.23 | -0.96 | - |
Earnings Before Taxes | -11.4% | -653,449,000 | -586,417,000 | -531,968,000 | -400,474,000 | -384,470,000 |
EBT Margin | -6.8% | -1.45 | -1.36 | -1.30 | -1.02 | - |
Interest Expenses | 0.0% | 2,577,000 | 2,576,000 | 2,576,000 | 2,575,000 | 2,577,000 |
Net Income | -11.5% | -654,588,000 | -586,965,000 | -532,497,000 | -400,640,000 | -384,770,000 |
Net Income Margin | -6.9% | -1.46 | -1.36 | -1.30 | -1.02 | - |
Free Cahsflow | 0.2% | -386,924,000 | -387,787,000 | -363,195,000 | -309,494,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -5.4% | 1,610 | 1,702 | 1,854 | 2,130 | 2,204 |
Current Assets | 5.4% | 1,192 | 1,131 | 1,037 | 1,113 | 1,114 |
Cash Equivalents | -10.5% | 142 | 158 | 215 | 574 | 492 |
Inventory | -18.2% | 52.00 | 63.00 | 60.00 | 37.00 | 31.00 |
Net PPE | -0.1% | 168 | 168 | 163 | 151 | 124 |
Goodwill | 0% | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
Liabilities | 1.0% | 1,550 | 1,535 | 1,535 | 1,597 | 1,559 |
Current Liabilities | 10.3% | 193 | 175 | 168 | 229 | 195 |
Shareholder's Equity | -63.9% | 60.00 | 167 | 319 | 533 | 645 |
Retained Earnings | -9.2% | -1,662 | -1,522 | -1,360 | -1,131 | -1,007 |
Additional Paid-In Capital | 1.5% | 1,742 | 1,716 | 1,704 | 1,682 | 1,658 |
Accumulated Depreciation | 13.1% | 70.00 | 61.00 | 55.00 | - | - |
Shares Outstanding | 0.2% | 103 | 102 | 102 | 102 | 102 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -4.7% | -309 | -295 | -270 | -221 | -209 |
Share Based Compensation | -3.2% | 95.00 | 98.00 | 112 | 121 | 151 |
Cashflow From Investing | 179.9% | 150 | -187 | -276 | -76.22 | -63.15 |
Cashflow From Financing | -0.8% | -189 | -187 | -173 | 3.00 | -66.82 |
95.3%
82.5%
54.5%
Y-axis is the maximum loss one would have experienced if Guardant Health was unfortunately bought at previous high price.
-27.7%
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -0.05 | -290,384 | 296,616 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 20.2 | -693,000 | 1,071,000 | -% |
2023-02-28 | Voya Investment Management LLC | added | 4.35 | -33,437,000 | 37,298,000 | 0.05% |
2023-02-24 | NATIXIS | sold off | -100 | -1,354,000 | - | -% |
2023-02-24 | SRS Capital Advisors, Inc. | unchanged | - | -2,280 | 2,720 | -% |
2023-02-21 | Adalta Capital Management LLC | reduced | -18.2 | -3,234,000 | 2,278,000 | 1.61% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | reduced | -41.21 | -14,179 | 5,821 | -% |
2023-02-21 | MACQUARIE GROUP LTD | sold off | -100 | -116,000 | - | -% |
2023-02-17 | TRUIST FINANCIAL CORP | reduced | -11.23 | -454,140 | 368,860 | -% |
2023-02-16 | HARBOUR INVESTMENTS, INC. | added | 2.65 | -5,413 | 11,587 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Mar 10, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 14, 2023 | viking global investors lp | 4.0% | 4,107,644 | SC 13G/A | |
Feb 13, 2023 | capital international investors | 7.7% | 7,879,355 | SC 13G | |
Feb 13, 2023 | capital research global investors | 2.0% | 2,001,782 | SC 13G/A | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 8.83% | 9,040,240 | SC 13G/A | |
Feb 03, 2023 | blackrock inc. | 5.4% | 5,495,293 | SC 13G | |
Mar 09, 2022 | blackrock inc. | 4.9% | 4,961,865 | SC 13G/A | |
Feb 11, 2022 | capital research global investors | 7.8% | 7,927,702 | SC 13G | |
Feb 10, 2022 | fmr llc | - | 0 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | - - | 0.48 -98.30% | 2.81 -90.06% | 7.07 -74.98% | 11.13 -60.62% |
Current Inflation | 0.29 -98.97% | 0.34 -98.80% | 2.36 -91.65% | 6.02 -78.70% | 9.49 -66.42% |
Very High Inflation | - - | 0.17 -99.40% | 1.84 -93.49% | 4.79 -83.05% | 7.59 -73.14% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 16, 2023 | 4 | Insider Trading | |
Mar 16, 2023 | 4 | Insider Trading | |
Mar 16, 2023 | 4 | Insider Trading | |
Mar 15, 2023 | 4 | Insider Trading | |
Mar 13, 2023 | 8-K | Current Report | |
Mar 10, 2023 | SC 13G/A | Major Ownership Report | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-14 | Talasaz AmirAli | bought | 112,188 | 26.3972 | 4,250 | co-chief executive officer |
2023-03-14 | Talasaz AmirAli | bought | 224,376 | 26.3972 | 8,500 | co-chief executive officer |
2023-03-13 | Talasaz AmirAli | bought | 513,107 | 25.6554 | 20,000 | co-chief executive officer |
2023-03-13 | Talasaz AmirAli | bought | 1,026,220 | 25.6554 | 40,000 | co-chief executive officer |
2023-03-04 | Joyce Meghan V. | acquired | - | - | 66.00 | - |
2023-03-03 | Kalia Kumud | sold | -207,466 | 31.9179 | -6,500 | chief information officer |
2023-03-01 | Saia John G. | acquired | - | - | 263 | chief legal officer |
2023-03-01 | Kalia Kumud | sold (taxes) | -7,222 | 29.36 | -246 | chief information officer |
Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue: | |||
Precision oncology testing | $ 392,049 | $ 304,312 | $ 236,324 |
Development services and other | 57,489 | 69,341 | 50,406 |
Total revenue | 449,538 | 373,653 | 286,730 |
Costs and operating expenses: | |||
Cost of precision oncology testing | 148,199 | 110,396 | 74,769 |
Cost of development services and other | 8,126 | 12,516 | 17,766 |
Research and development expense | 373,807 | 263,221 | 149,862 |
Sales and marketing expense | 299,828 | 191,881 | 106,513 |
General and administrative expense | 163,956 | 206,640 | 192,770 |
Total costs and operating expenses | 993,916 | 784,654 | 541,680 |
Loss from operations | (544,378) | (411,001) | (254,950) |
Interest income | 6,069 | 3,930 | 10,171 |
Interest expense | (2,577) | (2,577) | (4,766) |
Other income (expense), net | (12,778) | 25,178 | 3,641 |
Fair value adjustments of noncontrolling interest liability | (99,785) | 0 | 0 |
Loss before provision for income taxes | (653,449) | (384,470) | (245,904) |
Provision for income taxes | 1,139 | 300 | 379 |
Net loss | (654,588) | (384,770) | (246,283) |
Adjustment of redeemable noncontrolling interest | 0 | (20,900) | (7,500) |
Net loss attributable to Guardant Health, Inc. common stockholders - basic | (654,588) | (405,670) | (253,783) |
Net loss attributable to Guardant Health, Inc. common stockholders - diluted | $ (654,588) | $ (405,670) | $ (253,783) |
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share) | $ (6.41) | $ (4.00) | $ (2.60) |
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share) | $ (6.41) | $ (4.00) | $ (2.60) |
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares) | 102,178 | 101,314 | 97,504 |
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares) | 102,178 | 101,314 | 97,504 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 | ||
---|---|---|---|---|
Current assets: | ||||
Cash and cash equivalents | $ 141,647 | $ 492,202 | ||
Short-term marketable debt securities | 869,584 | 440,546 | ||
Accounts receivable, net | 97,256 | 97,652 | ||
Inventory, net | 51,598 | 30,674 | ||
Prepaid expenses and other current assets, net | 31,509 | 53,052 | ||
Total current assets | 1,191,594 | 1,114,126 | ||
Long-term marketable debt securities | 0 | 698,034 | ||
Property and equipment, net | 167,920 | 124,461 | ||
Right-of-use assets, net | 174,001 | 189,443 | ||
Intangible assets, net | 11,727 | 14,207 | ||
Goodwill | 3,290 | 3,290 | ||
Other assets, net | 61,453 | 60,938 | ||
Total Assets | [1] | 1,609,985 | 2,204,499 | |
Current liabilities: | ||||
Accounts payable and accrued liabilities | 175,817 | 105,361 | ||
Noncontrolling interest liability | 0 | 78,000 | ||
Deferred revenue | 17,403 | 11,326 | ||
Total current liabilities | 193,220 | 194,687 | ||
Convertible senior notes, net | 1,137,391 | 1,134,821 | ||
Long-term operating lease liabilities | 210,015 | 226,053 | ||
Other long-term liabilities | 9,179 | 3,933 | ||
Total Liabilities | [1] | 1,549,805 | 1,559,494 | |
Commitments and contingencies (Note 10) | ||||
Stockholders’ equity: | ||||
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2022 and 2021 | 0 | 0 | ||
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of December 31, 2022 and 2021; 102,619,383 and 101,767,446 shares issued and outstanding as of December 31, 2022 and 2021, respectively | 1 | 1 | ||
Additional paid-in capital | 1,742,114 | 1,657,593 | ||
Accumulated other comprehensive loss | (19,522) | (4,764) | ||
Accumulated deficit | (1,662,413) | (1,007,825) | ||
Total Stockholders’ Equity | 60,180 | 645,005 | ||
Total Liabilities and Stockholders’ Equity | $ 1,609,985 | $ 2,204,499 | ||
|